Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation

International Journal of Technology Assessment in Health Care

Volumn 21, Issue 1, 2005, Pages 47-54

  Shepherd, Jonathan ^a   Brodin, Håkan F T ^a   Cave, Carolyn Backer ^a   Waugh, Norman R ^b   Price, Alison ^a   Gabbay, John ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Chronic; Hepatitis C; Interferons; Meta analysis; Quality adjusted life years

Indexed keywords

COST EFFECTIVENESS; DATABASE SYSTEMS; GENES; MARKOV PROCESSES; MATHEMATICAL MODELS; PATIENT TREATMENT;

HEPATITIS; INTERFERON ALFA; QUALITY-ADJUSTED LIFE YEAR (QALY); SUSTAINED VIROLOGICAL RESPONSE RATE (SVR);

DISEASE CONTROL;

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; ECONOMIC EVALUATION; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; STATISTICAL MODEL; SYSTEMATIC REVIEW; VIRUS LOAD;

EID: 13644256036     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462305050063     Document Type: Review

References (25)

1. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855-865.
2. Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther. 2003;17:687-694.
3. Davis GL. Treatment of chronic hepatitis C. BMJ. 2001;323: 1141-1142.
4. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36:S145-S151.
5. Davis GL, Esteban MR, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1493-1499.
6. Di Bisceglie AM. Hepatitis C. Lancet. 1998;351:351-355.
7. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433-439.
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
9. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-á 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
10. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866-874.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with Interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
12. Myers RP, Regimbeau C, Thevenot T et al. Interferon for Interferon naive patients with chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002;CD000370.
13. National Institute for Clinical Excellence. Guidance on the use of ribavirin and interferon alpha for hepatitis C. London: National Institute for Clinical Excellence; 2000.
14. National Institute for Clinical Excellence (NICE). Interferon alfa (pegylaled and non pegylated) and ribavirin in the treatment of chronic hepatitis C (TA075). London: National Institute for Clinical Excellence; 2004.
15. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd ed. York York Publishing Services Ltd; 2001.
16. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
17. Poynard T, McHutchison J, Goodman Z, et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31:211-218.
18. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2004;8.
19. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review. Health Technol Assess 2000;4.
20. Siebert U, Sroczynski G, Rossol S, et al. Cost-effectivenes: of peginterferon 2 b plus ribavirin versus interferon 2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-432.
21. Thomas HC. Clinical features of viral hepatitis. In: Weatheral DT, Ledingham J, Warrell DA, eds. Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1996:2061-2069.
22. Verbaan HP, Widell HE, Bondeson TL, Lindgren SC. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol. 2002;14:627-633.
23. Wong JB. Interferon treatment for chronic hepatitis B or C infection: Costs and effectiveness. Acta Gastroenterol Belg 1998;61:238-242.
24. Wong JB. Estimating the cost-effectiveness of ribavirin and pegylated interferon alfa-2B for chronic hepatitis C. Hepatology. 2000;32:1062.
25. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs. JAMA. 1998;280:2088-2093.